SAN DIEGO, March 9, 2017 /PRNewswire/ --
Dr. Donnelly is an Internationally Recognized Animal Researcher, who the Company Believes Will Play an Important Role in the Development of Zander's NR2F6 Small Molecule Drug Development Program for Veterinary Applications in Treating Canine Cancer and Arthritis in Animals
Entest BioMedical Inc.'s (OTCPINK: ENTB) wholly owned subsidiary, Zander Therapeutics Inc., announced the appointment of Thomas Donnelly, DVM as its Senior Veterinarian Advisor. Dr. Donnelly is an internationally recognized veterinarian researcher and is a certified specialist in the field of laboratory animal medicine, a recognized specialty within the veterinary medical field.
Professor Donnelly's specialty is linking the understanding of animal diseases and their complexities with the development of novel therapies for humans and animals. This ability dovetails in perfectly with Zander Therapeutics' developmental model for veterinary biotechnology. Additionally, he will provide Zander with regulatory guidance, serve as a research adviser and provide direction for the Company's drug development related to animal therapeutics.
"As we move forward in veterinary small molecule drug development, it is extremely important to draw from such an expert as Dr. Donnelly in charting the course our research takes. His tremendous expertise and international reputation will help us facilitate our goal - to develop novel therapeutics to help dogs, cats and horses recover from common diseases that they are susceptible to such as arthritis and cancer," said David Koos, Ph.D., Chairman and CEO of Zander.
About Zander Therapeutics Inc.:
Zander Therapeutics is a wholly owned subsidiary of Entest BioMedical Inc. (OTCPink: ENTB), a publicly traded biotechnology company focused on veterinary medicine. The Company seeks to develop small molecule and immune stimulating therapies for veterinary applications.
Currently, the Company's major interest is in developing small molecule therapies for treating cancer and autoimmune diseases in animals, which include arthritis.
Zander Therapeutics Inc. is the exclusive licensee for veterinary applications of Regen BioPharma Inc.'s (OTCQB: RGBP) (OTCQB: RGBPP) intellectual property and technology relating to NR2F6. NR2F6 is a molecular switch known as an "orphan nuclear receptor", which controls genes associated with the immune response. Zander Therapeutics is solely focused on veterinary applications.
David Koos serves as Chairman and Chief Executive officer of Regen BioPharma, Inc. (OTCQB: RGBP), Entest BioMedical Inc. (OTCPINK: ENTB) and Zander Therapeutics Inc. (wholly owned by Entest BioMedical Inc.).
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Zander Therapeutics Inc. and Entest BioMedical Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
SOURCE Entest BioMedical Inc.